BiosparQ, has secured 3.4 million EUR in financing from the Dutch government. This funding comes in the form of an innovation credit, a loan from the government for innovation projects. BiosparQ. will be using this funding to accelerate the development, validation and certification of the DigiTOF platform for to the clinical market.
BiosparQ is based in Leiden and develops DigiTOF, an in vitro diagnostics solution for rapid diagnostics. DigiTOF is based on MALDI-TOF Mass spectrometry applied on single bacteria isolated directly from patient material. Ease of use, turnaround time of less than 20 minutes and a low cost per test will ensure a large variety of applications. “From the start we knew that the DigiTOF has the potential to bridge the gap in clinical diagnostics between patient and treatment. Now that we have obtained the support from the Dutch government and the positive feedback from the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), we are certain that DigiTOF is the way forward. We would like to thank everyone that made it possible for BiosparQ to grow and develop into the company it is today and we look forward to working with you to realize the potential that is the DigiTOF” Gerold de Valk, CEO.
https://www.hollandbio.nl/wp-content/uploads/2018/01/logo3.png00HollandBIOhttps://www.hollandbio.nl/wp-content/uploads/2018/01/logo3.pngHollandBIO2018-06-01 10:08:422018-06-04 10:15:38BiosparQ secures 3.4 million EUR
Schrijf je in voor de HollandBIO Weekly
HollandBIO is de belangenvereniging van biotech bedrijven in Nederland. Samen werken we aan ons toekomstideaal: een maatschappij waarin biotechnologie maximaal bijdraagt aan gezondheid, duurzaamheid en economische groei.
Laan van Nieuw Oost-Indië 131-133
2593 BM Den Haag
Laan van Nieuw Oost-Indië 131 E
2593 BM Den Haag